KZIA NASDAQ
Kazia Therapeutics Ltd ADR
1W: -3.1%
1M: -26.5%
3M: -29.1%
YTD: +85.4%
1Y: +35.3%
3Y: -82.0%
5Y: -98.3%
$9.27
-0.20 (-2.11%)
Weekly Expected Move ±9.3%
$8
$8
$9
$10
$11
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$42K
-98.2% ▼
5Y CAGR: -46.8%
Gross Profit
$42K
-98.2% ▼
5Y CAGR: -46.8%
Operating Income
-$14M
+50.0% ▲
Net Income
-$21M
+22.7% ▲
EPS (Diluted)
$-18.90
+65.6% ▲
EBITDA
-$13M
+50.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $15M | $10K | $555 | $2M | $42K |
| YoY Growth | +1430881.2% | -99.9% | -94.5% | +415755.9% | -98.2% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $15M | $10K | $555 | $2M | $42K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $15M | $20M | $16M | $17M | $7M |
| SG&A Expenses | $7M | $5M | $9M | $14M | $9M |
| Operating Expenses | $22M | $25M | $24M | $31M | $14M |
| Operating Income | -$6M | -$25M | -$24M | -$28M | -$14M |
| Operating Margin | -42.0% | -253990.0% | -4346661.1% | -1233.2% | -33850.0% |
| Interest Expense | $0 | $2K | $0 | $0 | $0 |
| Income Before Tax | -$9M | -$25M | -$21M | -$27M | -$22M |
| Tax Expense | -$484K | -$368K | -$271K | -$271K | -$2M |
| Net Income | -$8M | -$25M | -$20M | -$27M | -$21M |
| Net Margin | -55.5% | -250140.0% | -3687419.8% | -1160.2% | -49290.5% |
| EPS (Diluted) | $-35.80 | $-95.00 | $-55.00 | $-55.00 | $-18.90 |
| EBITDA | -$5M | -$24M | -$22M | -$27M | -$13M |
| Shares Outstanding | 235400 | 265000 | 368600 | 479600 | 1M |